Up a level |
Nathan, Paul, Hassel, Jessica C, Rutkowski, Piotr, Baurain, Jean-Francois, Butler, Marcus O, Schlaak, Max, Sullivan, Ryan J, Ochsenreither, Sebastian, Dummer, Reinhard, Kirkwood, John M et al (show 18 more authors)
(2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
NEW ENGLAND JOURNAL OF MEDICINE, 385 (13).
pp. 1196-1206.
Hassel, Jessica C, Piperno-Neumann, Sophie, Rutkowski, Piotr, Baurain, Jean-Francois, Schlaak, Max, Butler, Marcus O, Sullivan, Ryan J, Dummer, Reinhard, Kirkwood, John M, Orloff, Marlana et al (show 19 more authors)
(2023)
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
The New England journal of medicine, 389 (24).
pp. 2256-2266.
Sacco, Joseph J, Jackson, Richard, Corrie, Pippa, Danson, Sarah, Jeffry Evans, TR, Ochsenreither, Sebastian, Kumar, Satish, Goodman, Andrew, Larkin, James, Karydis, Ioannis et al (show 11 more authors)
(2024)
A three-arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
European Journal of Cancer, 202.
p. 114009.